Analysts’ Viewpoint on Albumin (as Excipient) Market Scenario
Rise in number of pharmaceutical & biotechnology companies and growth in usage of albumin in vaccine production are driving the global albumin (as excipient) market. Albumin is used in the development of COVID-19 vaccines due to its ability to guard against shear stress, prevent surface adsorption, and provide thermal stability. Human serum albumin is commonly used in drug delivery, drug development, and vaccine production. However, there has been a shift in preference for recombinant albumin since the last few years due to the guidance from regulatory authorities to eliminate or minimize the usage of animal-derived products or materials in the manufacture of protein-based therapeutics. Increase in demand for albumin (as excipient), especially in countries in Asia such as China and India, is augmenting the global market.
Albumin is commonly used in drug formulation, drug delivery, vaccines, and medical device coating. It is also commonly used in diagnostics and in vitro fertilization. Furthermore, it is used as culture medium and stabilizer. Albumin is widely used as a drug carrier in systems such as high albumin globular protein, albumin-drug nanoparticles, and pro-drugs. It is also used as a drug carrier for the treatment of various diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis. Albumin has the ability to bind to an extraordinarily diverse range of molecules, as it provides a depository for various compounds. This renders albumin ideal for usage as an excipient in vaccine and drug production.
Human serum albumin and recombinant albumin are the two types of albumin used as an excipient. Human serum albumin constitutes about 50% of human plasma protein and occurs naturally in the liver. It is proven to be an ideal stabilizer in pharmaceutical and biotech products. It is effective as a drug delivery vehicle, preferred for artificial media, and quite useful in cryopreservation and cell culture. Albumin test checks the albumin level in the blood. Low albumin or high albumin levels indicate issues with liver and kidney. The global albumin (as excipient) market is primarily driven by the increase in usage of albumin as a multifunctional excipient, rise in research & development activities, and launch of new products.
Albumin is a globular protein that is abundant in blood. It is necessary for blood osmotic pressure regulation. It protects globular proteins from oxidation by acting as a powerful antioxidant that prevents protein therapeutics from being modified. Albumin also acts as a blocking agent to prevent non-specific adsorption to glass & plastic surfaces and prevents aggregation of protein products during manufacture and delivery. Albumin has been used as a drug carrier in various systems including albumin fusion proteins, albumin-drug nanoparticles, and pro-drugs. It has also been used as a drug carrier to treat diseases such as rheumatoid arthritis, diabetes, cancer, and hepatitis.
In terms of product type, the human serum albumin segment accounted for significant share of the market in 2021. Human serum albumin (HSA) is a highly stable protein. The stability of albumin makes its handling and storage easier compared to typical globular proteins. The surface-active character of albumin makes it an ideal candidate to be used as a surfactant to prevent protein aggregation. It also has a high glass transition temperature and amphiphilic nature, which makes it an ideal excipient for cryoprotection. Launch of new products by key players is boosting the global market. In May 2020, Bio Products Laboratory (BPL) launched ALBUMINEX 5% and ALBUMINEX 25% for the treatment of hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome (ARDS), and cardiopulmonary bypass.
Based on application, the drug delivery segment held major share of the global albumin (as excipient) market in 2021. Human serum albumin is a better carrier in drug delivery systems due to properties such as multiple ligand binding capacity, nontoxicity, and biodegradable non-immunogenic nature. This is likely to propel the segment during the forecast period. The vaccines segment is driven by a shift toward the usage of recombinant albumin among vaccine manufacturers.
In terms of end-user, the pharmaceutical & biotechnology industry segment is projected to account for major share of the global albumin (as excipient) market during the forecast period. Growth of the segment can be ascribed to the increase in demand for advanced medications due to the rise in prevalence of chronic diseases such as liver and kidney diseases. Surge in acceptance of human serum albumin (HSA) and recombinant albumin for drug formulation, vaccine production, and culture media preparation is also anticipated to propel the pharmaceutical & biotechnology industry segment during the forecast period.
North America held the largest share of around 38% of the global albumin (as excipient) market in 2021. It is expected to be a highly lucrative region of the global market during the forecast period. North America's dominance of the global albumin (as excipient) market can be ascribed to the rise in prevalence of major chronic diseases along with the rapid increase in geriatric population in the region. The U.S. dominated the market in North America owing to the increase in demand for albumin in clinical research activities, rise in focus on non-therapeutic applications of albumin, and surge in manufacture of immunoglobulin in the country. Additionally, presence of key players and early adoption of technologically advanced products are projected to drive the market in the country.
Asia Pacific is anticipated to be the fastest growing region of the global albumin (as excipient) market during the forecast period. Aging population, increase in healthcare expenditure, and surge in competition in albumin manufacturing in countries such as China, Japan, and Australia are expected to propel the albumin (as excipient) market in the region.
The global albumin (as excipient) market is consolidated, with the presence of a small number of leading players. Most of the companies are investing significantly in research & development activities, primarily to introduce innovative albumin-based products for the treatment of chronic diseases. Expansion of product portfolio and mergers & acquisitions are the key strategies adopted by the key players in the global albumin (as excipient) market. Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring (CSL), Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA), and Takeda Pharmaceutical Company Limited (Shire) are the key players operating in the global market.
Each of these players has been profiled in the albumin (as excipient) market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.
|
Attribute |
Detail |
|
Market Size Value in 2021 |
US$ 0.81 Bn |
|
Market Forecast Value in 2031 |
More than US$ 1.7 Bn |
|
Growth Rate (CAGR) |
6.3% |
|
Forecast Period |
2022–2031 |
|
Historical Data Available for |
2017–2020 |
|
Quantitative Units |
US$ Mn for Value & Kg for Volume |
|
Market Analysis |
It includes segment analysis well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis. |
|
Competition Landscape |
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
Regions Covered |
|
|
Countries Covered |
|
|
Companies Profiled |
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
The global albumin (as excipient) market was valued at US$ 0.81 Bn in 2021.
The global albumin (as excipient) market is projected to reach more than US$ 1.7 Bn by 2031.
The global albumin (as excipient) market is anticipated to grow at a CAGR of 6.3% from 2022 to 2031.
Increase in usage of albumin as multifunctional excipient is expected to drive the global albumin (as excipient) market.
North America is likely to account for major share of the global albumin (as excipient) market during the forecast period.
Prominent players in the global albumin (as excipient) market include Albumedix Ltd., Albumin Therapeutics, LLC (Albumin Bioscience), Biotest AG, CSL Behring (CSL), Grifols, S.A, HiMedia Laboratories, InVitria, Medxbio Pte Ltd., Octapharma AG, RayBiotech, Inc., SeraCare Life Sciences, Sigma-Aldrich Co. (Merck KGaA) and Takeda Pharmaceutical Company Limited (Shire).
1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunity
4.3. Global Albumin (as Excipient) Market Forecast
4.4. Global Albumin (as Excipient) Market Outlook
5. Market Outlook
5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)
5.2. Technological Advancement
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type
6.1. Global Albumin (as Excipient) Market Analysis and Forecast, by Product Type
6.2. Introduction
6.3. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
6.4. Global Albumin (as Excipient) Market Forecast, by Product Type
6.4.1. Human Serum Albumin
6.4.2. Recombinant Albumin
6.5. Global Albumin (as Excipient) Market Analysis, by Product Type
7. Global Albumin (as Excipient) Market Analysis and Forecast, by Application
7.1. Introduction
7.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
7.3. Global Albumin (as Excipient) Market Forecast, by Application
7.3.1. Human Serum Albumin Applications
7.3.1.1. Drug Formulation
7.3.1.2. Drug Delivery
7.3.1.3. Vaccines
7.3.1.4. Medical Device Coating
7.3.1.5. Culture Medium & Stabilizer
7.3.1.6. Diagnostics
7.3.1.7. In Vitro Fertilization
7.3.2. Recombinant Albumin
7.3.2.1. Drug Formulation
7.3.2.2. Drug Delivery
7.3.2.3. Vaccines
7.3.2.4. Medical Device Coating
7.3.2.5. Culture Medium & Stabilizer
7.3.2.6. Diagnostics
7.3.2.7. In Vitro Fertilization
7.4. Global Albumin (as Excipient) Market Analysis, by Application
8. Global Albumin (as Excipient) Market Analysis and Forecast, by End-user
8.1. Introduction
8.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
8.3. Global Albumin (as Excipient) Market Forecast, by End-user
8.3.1. Pharmaceutical & Biotechnology Industry
8.3.2. Research Institutes
8.3.3. Others
8.4. Global Albumin (as Excipient) Market Analysis, by End-user
9. Global Albumin (as Excipient) Market Analysis and Forecast, by Region
9.1. Global Albumin (as Excipient) Market Analysis, by Region
9.2. Global Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Region
9.3. Global Albumin (as Excipient) Market Forecast, by Region
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
10. North America Albumin (as Excipient) Market Analysis
10.1. North America Albumin (as Excipient) Market Overview
10.2. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Country
10.3. North America Albumin (as Excipient) Market Forecast, by Country
10.3.1. U.S.
10.3.2. Canada
10.4. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
10.5. North America Albumin (as Excipient) Market Forecast, by Product Type
10.5.1. Human Serum Albumin
10.5.2. Recombinant Albumin
10.6. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
10.7. North America Albumin (as Excipient) Market Forecast, by Application
10.7.1. Human Serum Albumin Applications
10.7.1.1. Drug Formulation
10.7.1.2. Drug Delivery
10.7.1.3. Vaccines
10.7.1.4. Medical Device Coating
10.7.1.5. Culture Medium & Stabilizer
10.7.1.6. Diagnostics
10.7.1.7. In Vitro Fertilization
10.7.2. Recombinant Albumin
10.7.2.1. Drug Formulation
10.7.2.2. Drug Delivery
10.7.2.3. Vaccines
10.7.2.4. Medical Device Coating
10.7.2.5. Culture Medium & Stabilizer
10.7.2.6. Diagnostics
10.7.2.7. In Vitro Fertilization
10.8. North America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
10.9. North America Albumin (as Excipient) Market Forecast, by End-user
10.9.1. Pharmaceutical & Biotechnology Industry
10.9.2. Research Institutes
10.9.3. Others
11. Europe Albumin (as Excipient) Market Analysis
11.1. Europe Albumin (as Excipient) Market Overview
11.2. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
11.3. Europe Albumin (as Excipient) Market Forecast, by Countries/Sub-region
11.3.1. Germany
11.3.2. France
11.3.3. U.K.
11.3.4. Italy
11.3.5. Spain
11.3.6. Rest of Europe
11.4. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
11.5. Europe Albumin (as Excipient) Market Forecast, by Product Type
11.5.1. Human Serum Albumin
11.5.2. Recombinant Albumin
11.6. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
11.7. Europe Albumin (as Excipient) Market Forecast, by Application
11.7.1. Human Serum Albumin Applications
11.7.1.1. Drug Formulation
11.7.1.2. Drug Delivery
11.7.1.3. Vaccines
11.7.1.4. Medical Device Coating
11.7.1.5. Culture Medium & Stabilizer
11.7.1.6. Diagnostics
11.7.1.7. In Vitro Fertilization
11.7.2. Recombinant Albumin
11.7.2.1. Drug Formulation
11.7.2.2. Drug Delivery
11.7.2.3. Vaccines
11.7.2.4. Medical Device Coating
11.7.2.5. Culture Medium & Stabilizer
11.7.2.6. Diagnostics
11.7.2.7. In Vitro Fertilization
11.8. Europe Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
11.9. Europe Albumin (as Excipient) Market Forecast, by End-user
11.9.1. Pharmaceutical & Biotechnology Industry
11.9.2. Research Institutes
11.9.3. Others
12. Asia Pacific Albumin (as Excipient) Market Analysis
12.1. Asia Pacific Albumin (as Excipient) Market Overview
12.2. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
12.3. Asia Pacific Albumin (as Excipient) Market Forecast, by Countries/Sub-region
12.3.1. Japan
12.3.2. China
12.3.3. India
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
12.5. Asia Pacific Albumin (as Excipient) Market Forecast, by Product Type
12.5.1. Human Serum Albumin
12.5.2. Recombinant Albumin
12.6. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
12.7. Asia Pacific Albumin (as Excipient) Market Forecast, by Application
12.7.1. Human Serum Albumin Applications
12.7.1.1. Drug Formulation
12.7.1.2. Drug Delivery
12.7.1.3. Vaccines
12.7.1.4. Medical Device Coating
12.7.1.5. Culture Medium & Stabilizer
12.7.1.6. Diagnostics
12.7.1.7. In Vitro Fertilization
12.7.2. Recombinant Albumin
12.7.2.1. Drug Formulation
12.7.2.2. Drug Delivery
12.7.2.3. Vaccines
12.7.2.4. Medical Device Coating
12.7.2.5. Culture Medium & Stabilizer
12.7.2.6. Diagnostics
12.7.2.7. In Vitro Fertilization
12.8. Asia Pacific Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
12.9. Asia Pacific Albumin (as Excipient) Market Forecast, by End-user
12.9.1. Pharmaceutical & Biotechnology Industry
12.9.2. Research Institutes
12.9.3. Others
13. Latin America Albumin (as Excipient) Market Analysis
13.1. Latin America Albumin (as Excipient) Market Overview
13.2. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
13.3. Latin America Albumin (as Excipient) Market Forecast, by Countries/Sub-region
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
13.5. Latin America Albumin (as Excipient) Market Forecast, by Product Type
13.5.1. Human Serum Albumin
13.5.2. Recombinant Albumin
13.6. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
13.7. Latin America Albumin (as Excipient) Market Forecast, by Application
13.7.1. Human Serum Albumin Applications
13.7.1.1. Drug Formulation
13.7.1.2. Drug Delivery
13.7.1.3. Vaccines
13.7.1.4. Medical Device Coating
13.7.1.5. Culture Medium & Stabilizer
13.7.1.6. Diagnostics
13.7.1.7. In Vitro Fertilization
13.7.2. Recombinant Albumin
13.7.2.1. Drug Formulation
13.7.2.2. Drug Delivery
13.7.2.3. Vaccines
13.7.2.4. Medical Device Coating
13.7.2.5. Culture Medium & Stabilizer
13.7.2.6. Diagnostics
13.7.2.7. In Vitro Fertilization
13.8. Latin America Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
13.9. Latin America Albumin (as Excipient) Market Forecast, by End-user
13.9.1. Pharmaceutical & Biotechnology Industry
13.9.2. Research Institutes
13.9.3. Others
14. Middle East & Africa Albumin (as Excipient) Market Analysis
14.1. Middle East & Africa Albumin (as Excipient) Market Overview
14.2. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Countries/Sub-region
14.3. Middle East & Africa Albumin (as Excipient) Market Forecast, by Countries/Sub-region
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of MEA
14.4. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Product Type
14.5. Middle East & Africa Albumin (as Excipient) Market Forecast, by Product Type
14.5.1. Human Serum Albumin
14.5.2. Recombinant Albumin
14.6. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by Application
14.7. Middle East & Africa Albumin (as Excipient) Market Forecast, by Application
14.7.1. Human Serum Albumin Applications
14.7.1.1. Drug Formulation
14.7.1.2. Drug Delivery
14.7.1.3. Vaccines
14.7.1.4. Medical Device Coating
14.7.1.5. Culture Medium & Stabilizer
14.7.1.6. Diagnostics
14.7.1.7. In Vitro Fertilization
14.7.2. Recombinant Albumin
14.7.2.1. Drug Formulation
14.7.2.2. Drug Delivery
14.7.2.3. Vaccines
14.7.2.4. Medical Device Coating
14.7.2.5. Culture Medium & Stabilizer
14.7.2.6. Diagnostics
14.7.2.7. In Vitro Fertilization
14.8. Middle East & Africa Albumin (as Excipient) Market Value Share and Attractiveness Analysis, by End-user
14.9. Middle East & Africa Albumin (as Excipient) Market Forecast, by End-user
14.9.1. Pharmaceutical & Biotechnology Industry
14.9.2. Research Institutes
14.9.3. Others
15. Competition Landscape
15.1. Market Player - Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis/Ranking, by Company, 2021
15.3. Company Profiles
15.3.1. Albumedix Ltd.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Financial Overview
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Albumin Therapeutics, LLC (Albumin Bioscience)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Financial Overview
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Biotest AG
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Financial Overview
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. CSL Behring (CSL)
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Financial Overview
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Grifols, S.A.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Financial Overview
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. HiMedia Laboratories
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Financial Overview
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. InVitria
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Financial Overview
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Medxbio Pte Ltd
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Financial Overview
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Octapharma AG
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. Financial Overview
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. RayBiotech, Inc.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Financial Overview
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
15.3.11. SeraCare Life Sciences
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Portfolio
15.3.11.3. Financial Overview
15.3.11.4. SWOT Analysis
15.3.11.5. Strategic Overview
15.3.12. Sigma-Aldrich Co. (Merck KGaA)
15.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.12.2. Product Portfolio
15.3.12.3. Financial Overview
15.3.12.4. SWOT Analysis
15.3.12.5. Strategic Overview
15.3.13. Takeda Pharmaceutical Company Limited (Shire)
15.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.13.2. Product Portfolio
15.3.13.3. Financial Overview
15.3.13.4. SWOT Analysis
15.3.13.5. Strategic Overview
List of Tables
Table 01: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 02: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 03: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Application, 2017–2031
Table 05: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 06: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 07: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 08: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 09: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 10: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 11: Global Albumin (as Excipient) Market Volume (Kg) Forecast, by Region, 2017–2031
Table 12: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 13: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031
Table 14: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 15: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 16: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 17: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 18: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 19: North America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 20: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 21: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 22: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031
Table 23: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 24: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 25: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 26: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 27: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 28: Europe Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 29: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 30: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 31: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031
Table 32: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 33: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 34: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 35: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 36: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 37: Asia Pacific Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 38: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 39: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 40: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031
Table 41: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 42: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 43: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 44: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 45: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 46: Latin America Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 47: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
Table 48: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 49: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Country/Sub-region, 2017–2031
Table 50: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Product Type, 2017–2031
Table 51: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Product Type, 2017–2031
Table 52: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 53: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Human Serum Albumin Applications, 2017–2031
Table 54: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 55: Middle East & Africa Albumin (as Excipient) Market Volume (Kg) Forecast, by Recombinant Albumin Applications, 2017–2031
Table 56: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Albumin (as Excipient) Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Albumin (as Excipient) Market Volume (Kg) Forecast, 2017–2031
Figure 03: Global Albumin (as Excipient) Market Value Share, by Product Type, 2021
Figure 04: Global Albumin (as Excipient) Market Value Share, by End-user, 2021
Figure 05: Global Albumin (as Excipient) Market Value Share, by Application (Human Serum Albumin Applications) (2021)
Figure 06: Global Albumin (as Excipient) Market Value Share, by Region, 2021
Figure 07: Global Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 08: Global Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 09: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Human Serum Albumin, 2017–2031
Figure 10: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Recombinant Albumin, 2017–2031
Figure 11: Global Albumin (as Excipient) Market Value Share Analysis, by Application, 2021 and 2031
Figure 12: Global Albumin (as Excipient) Market Attractiveness, by Application, 2022–2031
Figure 13: Global Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 14: Global Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 15: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Formulation, 2017–2031
Figure 16: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Delivery, 2017–2031
Figure 17: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Vaccines, 2017–2031
Figure 18: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Medical Device Coating, 2017–2031
Figure 19: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Culture Medium & Stabilizer, 2017–2031
Figure 20: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Diagnostics, 2017–2031
Figure 21: Global Albumin (as Excipient) Market Revenue (US$ Mn), by In Vitro Fertilization, 2017–2031
Figure 22: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Formulation, 2017–2031
Figure 23: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Drug Delivery, 2017–2031
Figure 24: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Vaccines, 2017–2031
Figure 25: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Medical Device Coating, 2017–2031
Figure 26: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Culture Medium & Stabilizer, 2017–2031
Figure 27: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Diagnostics, 2017–2031
Figure 28: Global Albumin (as Excipient) Market Revenue (US$ Mn), by In Vitro Fertilization, 2017–2031
Figure 29: Global Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 30: Global Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 31: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Pharmaceutical & Biotechnology Industry, 2017–2031
Figure 32: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Specialty Centers, 2017–2031
Figure 33: Global Albumin (as Excipient) Market Revenue (US$ Mn), by Others, 2017–2031
Figure 34: Global Albumin (as Excipient) Market Value Share Analysis, by Region, 2021 and 2031
Figure 35: Global Albumin (as Excipient) Market Attractiveness, by Region, 2022-2031
Figure 36: North America Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 37: North America Albumin (as Excipient) Market Value Share (%), by Country, 2021 and 2031
Figure 38: North America Albumin (as Excipient) Market Attractiveness, by Country, 2022–2031
Figure 39: North America Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 40: North America Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 41: North America Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 42: North America Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031
Figure 43: North America Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 44: North America Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031
Figure 45: North America Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 46: North America Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 47: Europe Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 48: Europe Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 49: Europe Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031
Figure 50: Europe Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 51: Europe Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 52: Europe Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 53: Europe Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031
Figure 54: Europe Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 55: Europe Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031
Figure 56: Europe Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 57: Europe Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 58: Asia Pacific Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 59: Asia Pacific Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 60: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031
Figure 61: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 62: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 63: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 64: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031
Figure 65: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 66: Asia Pacific Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031
Figure 67: Asia Pacific Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 68: Asia Pacific Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 69: Latin America Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 70: Latin America Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 71: Latin America Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031
Figure 72: Latin America Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 73: Latin America Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 74: Latin America Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 75: Latin America Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031
Figure 76: Latin America Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 77: Latin America Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031
Figure 78: Latin America Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 79: Latin America Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 80: Middle East & Africa Albumin (as Excipient) Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 81: Middle East & Africa Albumin (as Excipient) Market Value Share (%), by Country/Sub-region, 2021 and 2031
Figure 82: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Country/Sub-region, 2022–2031
Figure 83: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Product Type, 2021 and 2031
Figure 84: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Product Type, 2022–2031
Figure 85: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Human Serum Albumin Applications, 2021 and 2031
Figure 86: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Human Serum Albumin Applications, 2022–2031
Figure 87: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by Recombinant Albumin Applications, 2021 and 2031
Figure 88: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by Human Recombinant Applications, 2022–2031
Figure 89: Middle East & Africa Albumin (as Excipient) Market Value Share Analysis, by End-user, 2021 and 2031
Figure 90: Middle East & Africa Albumin (as Excipient) Market Attractiveness, by End-user, 2022–2031
Figure 91: Global Albumin (as Excipient) Market Share, by Company, 2021
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Albumin (as Excipient) Market
